Vicarious Surgical (NYSE:RBOT – Get Free Report) and Sight Sciences (NASDAQ:SGHT – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations and institutional ownership.
Profitability
This table compares Vicarious Surgical and Sight Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vicarious Surgical | N/A | -184.13% | -112.50% |
| Sight Sciences | -60.63% | -61.59% | -36.11% |
Analyst Ratings
This is a summary of recent ratings and price targets for Vicarious Surgical and Sight Sciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vicarious Surgical | 1 | 2 | 0 | 0 | 1.67 |
| Sight Sciences | 1 | 3 | 4 | 1 | 2.56 |
Earnings and Valuation
This table compares Vicarious Surgical and Sight Sciences”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vicarious Surgical | N/A | N/A | -$63.22 million | ($9.05) | -0.22 |
| Sight Sciences | $79.87 million | 3.48 | -$51.51 million | ($0.90) | -5.83 |
Sight Sciences has higher revenue and earnings than Vicarious Surgical. Sight Sciences is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Vicarious Surgical has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 2.41, indicating that its share price is 141% more volatile than the S&P 500.
Insider and Institutional Ownership
47.3% of Vicarious Surgical shares are held by institutional investors. Comparatively, 55.5% of Sight Sciences shares are held by institutional investors. 10.0% of Vicarious Surgical shares are held by company insiders. Comparatively, 28.9% of Sight Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Sight Sciences beats Vicarious Surgical on 11 of the 14 factors compared between the two stocks.
About Vicarious Surgical
Vicarious Surgical Inc. operates as a robotics technology company in the United States. The company focuses on developing and commercializing Vicarious System, a single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. Vicarious Surgical Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
About Sight Sciences
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.
Receive News & Ratings for Vicarious Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vicarious Surgical and related companies with MarketBeat.com's FREE daily email newsletter.
